Olema Pharmaceuticals (OLMA) Expected to Announce Earnings on Wednesday

Olema Pharmaceuticals (NASDAQ:OLMA) is expected to be releasing its Q1 2025 earnings data before the market opens on Wednesday, May 14th. Analysts expect Olema Pharmaceuticals to post earnings of ($0.52) per share for the quarter.

Olema Pharmaceuticals (NASDAQ:OLMA) last announced its quarterly earnings data on Tuesday, March 18th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.12. On average, analysts expect Olema Pharmaceuticals to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Olema Pharmaceuticals Trading Up 3.5%

NASDAQ OLMA opened at $4.76 on Tuesday. Olema Pharmaceuticals has a 12 month low of $2.86 and a 12 month high of $16.62. The stock has a 50 day moving average of $4.28 and a 200-day moving average of $6.24. The company has a market cap of $325.40 million, a PE ratio of -2.17 and a beta of 2.03.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Olema Pharmaceuticals in a research report on Monday, April 28th. JPMorgan Chase & Co. cut their price target on Olema Pharmaceuticals from $30.00 to $28.00 and set an “overweight” rating for the company in a report on Friday, March 28th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $25.00 price objective (down from $30.00) on shares of Olema Pharmaceuticals in a research report on Wednesday, March 19th.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.